What Is Selank? Benefits, Research & Safety
A synthetic peptide based on tuftsin, developed in Russia for anxiolytic and nootropic properties, approved there for anxiety and neurasthenia.
UK summary: Not a licensed UK medicine. Russian-developed nootropic / anxiolytic peptide; some human trial data exists but most published in Russian-language journals with limited independent replication.
Quick Facts
Overview
Selank — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Russian-developed nootropic / anxiolytic peptide; some human trial data exists but most published in Russian-language journals with limited independent replication.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed. Research compound only.
- EU: Not approved by EMA. Not available as a pharmaceutical.
- Notes: Selank is an approved pharmaceutical in Russia for anxiety and neurasthenia. It is not approved in the UK, EU, or USA. Products marketed outside Russia should be viewed with caution regarding quality and authenticity.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Non-addictive replacement for diazepam or other benzodiazepines.
- Cures generalised anxiety disorder.
- Safe daily nootropic with no comedown.
- Drug-tested clean for athletes.
07Common internet claims
- Russian-pharmacy-approved anxiolytic with no side effects.
- Marketed as a nasal spray smart drug for high-pressure work.
- Recommended for off-label combat-veteran PTSD self-treatment.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Effective alternative to benzodiazepines for anxiety” | C | Limited | High | Some small human studies report anxiolytic effects without sedation; not a licensed UK anxiolytic and not directly compared to benzodiazepines in robust trials. |
| “Non-addictive nootropic” | C | Limited | Moderate | No published evidence of dependence; long-term data are limited. |
| “Safer than prescription anxiety medicines” | E | No | High | Comparative safety claims need comparative trials; none exists. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Nasal irritation reported by intranasal users.
- Headaches and changes in olfaction at higher doses.
- Unknown interactions with SSRIs, SNRIs, benzodiazepines, and beta-blockers.
- Long-term effects on neurotransmitter systems unstudied outside Russia.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed. Research compound only.
14EU legal position
Not approved by EMA. Not available as a pharmaceutical.
15What this page cannot tell you
- Whether a UK-purchased nasal spray contains the labelled peptide at the labelled concentration.
- How it interacts with prescribed SSRIs or benzodiazepines a UK patient is already taking.
- Whether tolerance develops with chronic use.
- What the WADA in-competition status is for athletes.
16Last reviewed
17Citation quality score
18Research gaps
- Most positive human data appears in Russian-language journals without independent replication.
- No registered Western Phase 3 trials.
- Long-term safety in non-Russian populations unstudied.
- Mechanism of anxiolytic action not fully characterised.
19Safer alternatives / established care pathways
- GP review and licensed UK anxiolytic (SSRI, SNRI, or short-course benzodiazepine where clinically indicated).
- NICE-recommended CBT or other talking therapy via NHS Talking Therapies.
- Structured sleep, caffeine, and alcohol review before adding any compound.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Selank a licensed UK medicine?
- What licensed UK anxiety treatments should I consider first?
- What is the quality of the existing Selank evidence base?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Anxiolytic effects without sedation or dependence
- 2Potential nootropic and memory-enhancing effects
- 3Improved stress tolerance and adaptation
- 4Immunomodulatory properties
- 5Increased BDNF expression
- 6Possible antidepressant effects
- 7Neuroprotective properties in some models
Claim vs Evidence
How popular claims about Selank stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Effective alternative to benzodiazepines for anxiety” | C | Limited | High | Some small human studies report anxiolytic effects without sedation; not a licensed UK anxiolytic and not directly compared to benzodiazepines in robust trials. |
| “Non-addictive nootropic” | C | Limited | Moderate | No published evidence of dependence; long-term data are limited. |
| “Safer than prescription anxiety medicines” | E | No | High | Comparative safety claims need comparative trials; none exists. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 200-300 mcg intranasally per dose (Russian product standard) |
| Frequency | 2-3 times daily |
| Duration | 2-4 weeks in Russian clinical practice |
| Notes | These protocols reflect Russian pharmaceutical use. Selank is not approved in the UK/EU. Any use should be under medical supervision. Nasal administration is most common, though injectable forms exist. |
Administration Routes
Routes studied in research settings (educational only):
- Intranasal (nasal spray - most common)
- Subcutaneous injection (research settings)
| Half-Life | Stability |
|---|---|
| Short; several minutes to hours. Effects may persist longer than plasma levels suggest. | Nasal spray formulations stable under appropriate storage conditions |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Generally well-tolerated in Russian clinical use
- Mild nasal irritation with spray administration
- Fatigue in some individuals
- Headache (infrequent)
Rare Risks & Concerns
- Long-term effects not fully characterised
- Limited safety data from non-Russian sources
- Potential for drug interactions not well studied
Contraindications
- Pregnancy and breastfeeding
- Known allergy to peptide components
- Concurrent use with CNS-active medications (caution)
- Children (limited safety data)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed. Research compound only.
🇪🇺 European Union
Not approved by EMA. Not available as a pharmaceutical.
Clinical Studies Summary
[Optimization of the treatment of anxiety disorders with selank].
The results extend therapeutic possibilities of treatment of anxietyspectrum disorders with the combination of benzodiazepine tranquilizers and selank.
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
The clinical-biological study revealed that patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders. The increase of this parameter and stronger positive correlations with anxiety level were observed during the treatment with selank mostly in patients with GAD.
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.
[Comparison of anticoagulant effects of regulatory proline-containing oligopeptides. Specificity of glyprolines, semax, and selank and potential of their practical application].
The problem of the role of RPs in hemostatic processes becomes particularly significant since, first, the peptides are widespread in nature both in animal and plant tissues, second, there is a relationship between the peptide structure and function and, third, both natural and synthetic peptides are used in practical medicine to correct functions of some factors of the hemostatic system.
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Illicit use can lead to significant toxicities related to abuse, dependence, and subsequent withdrawal syndromes. Significant evaluation of developing agents with GABA properties should be conducted to determine abuse potential before public access ensues.
Functional Connectomic Approach to Studying Selank and Semax Effects.
Between-group alongwith between-condition differences were revealed in FC between the right amygdala and a region in fusiform, inferior and middle temporal as well as parahippocampal gyri in the right hemisphere. Post hoc analysis allowed us to define both general and specific effects of Selank and Semax on FC between the right amygdala and the right temporal cortex for the first time.
Registered Trials & Regulatory Status
1 of 1 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Effects of Transcranial Magnetic Stimulation on Object Recognition
Status: Completed · 13 participants · National Institute of Neurological Disorders and Stroke (NINDS)
Conditions: Repetitive TMS (rTMS), Sham rTMS, Bilateral rTMS
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Selank?
Source research-grade Selank from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Selank
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Selank a licensed UK medicine?
- What licensed UK anxiety treatments should I consider first?
- What is the quality of the existing Selank evidence base?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
Semax
A synthetic peptide based on ACTH, developed in Russia as a nootropic and neuroprotectant, approved there for cognitive disorders and stroke.
Learn moreDSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreDihexa
An angiotensin IV analogue and potent nootropic research compound with dramatic effects on memory and cognitive function in preclinical studies.
Learn more